Precision Medicine Meets Antibiotics
By: The Burrill Report | Source: burrillreport.com
The Centers for Disease Control and Prevention sounded the alarm on “nightmare bacteria” that pose an increasing threat because of their resistance to the strongest weapons in today’s antibiotics arsenal. David Martin, CEO of AvidBiotics, says we’ve created the problem through the ubiquitous use of broad spectrum antibiotics. He thinks the answer to attacking resistant strains of bacteria lies in the use of extremely narrow spectrum drugs.
Read or purchase full article from: burrillreport.com
Press Releases
Pylum Biosciences Collaborates on Research Published in the Journal Nature
AvidBiotics’ Scientists Co-author Publication in Science Translational Medicine Describing A New Class of Targeted Antibacterial Agents for Clostridium difficile
Study Published in mBio Shows that Avidocin™ Proteins Prevent Clostridium Difficile Infection in Mice without Harming Protective Gut Bacteria
AvidBiotics Granted U.S. Patent for Bactericidal Proteins that Selectively Kill C. Difficile
AvidBiotics Awarded SBIR Grant for Avidocin™ Antibacterial Proteins Against Clostridium difficile
Articles